JNK-IN-8 (GMP)

JNK-IN-8 (JNK Inhibitor XVI) (GMP) is JNK-IN-8 (HY-13319) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. JNK-IN-8 is a potent JNK inhibitor with IC50s of 4.7 nM, 18.7 nM, and 1 nM for JNK1, JNK2, and JNK3, respectively[1].

Product Specifications

CAS Number

[1410880-22-6]

Product Name Alternative

JNK Inhibitor XVI (GMP)

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

JNK

Type

GMP Small Molecules

Related Pathways

MAPK/ERK Pathway

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/jnk-in-8-gmp.html

Solubility

10 mM in DMSO

Smiles

CC1=CC(NC(C2=CC=CC(NC(/C=C/CN(C)C)=O)=C2)=O)=CC=C1NC3=NC=CC(C4=CN=CC=C4)=N3

Molecular Formula

C29H29N7O2

Molecular Weight

507.59

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Bengoa-Vergniory N, et al. A switch from canonical to noncanonical Wnt signaling mediates early differentiation of human neural stem cells. Stem Cells. 2014 Dec;32 (12) :3196-208. |[2]Xiao X, et al. Targeting JNK pathway promotes human hematopoietic stem cell expansion. Cell Discov. 2019 Jan 8;5:2.